摘要
目的:探讨厄洛替尼治疗表皮生长因子受体(EGFR)敏感突变肺腺癌对血管内皮功能及机体慢性炎症反应的影响。方法 :选择晩期EGFR敏感突变肺腺癌患者80例,按照患者经济情况及患者自我意愿分为两组(观察组与对照组),均为40例。对照组针对肺腺癌实施针对性治疗,如化疗、放疗机及中药治疗,观察组单用厄洛替尼,对所有患者随访6个月,比较治疗后两组ET-1、NO水平变化,治疗后两组炎症:IL-6、TNF-α及hs-CRP等水平变化,治疗后两组氧化因子:SOD、GSH-px和MDA水平变化,治疗后两组应激因子:皮质醇、肾上腺素和去甲肾上腺素三种应激因子水平变化。结果:治疗后,观察组ET-1水平低于对照组(P<0.05),NO水平高于对照组(P<0.05),观察组炎性相关因子如:IL-6、TNF-α及hs-CRP等水平均显著低于对照组(P<0.05),观察组SOD和GSH-px两种氧化因子水平大于对照组(P<0.05),MDA水平小于对照组(P<0.05),观察组皮质醇、肾上腺素和去甲肾上腺素三种应激因子水平均明显小于对照组(P<0.05)。结论:厄洛替尼治疗EGFR敏感突变肺腺癌,能显著改善患者血管内皮功能,降低机体炎症反应及应激反应,提高机体抗氧化能力,从而改善患者预后。
Objective:To investigate the effect of erlotinib on EGFR-sensitive mutant lung adenocarcinoma on endothelial function and chronic inflammation.Methods:80 patients with EGFR-sensitive mutational adenocarcinoma were divided into two groups(observation group and control group)according to the economic situation of the patient and the patient's self-willedness.Patients in the control group were treated with targeted therapy for lung adenocarcinoma,such as chemotherapy or radiotherapy,and erlotinib was used in the observation group only.All patients were followed for 6 months.changes in ET-1 and NO levels in the two groups after treatment were compared.In the latter two groups of inflammation:levels of IL-6,TNF-αand hs-CRP were changed.After treatment,the levels of oxidative factors:SOD,GSH-px and MDA in the two groups were changed.After treatment,stress factors:Cortisol and adrenaline Changes in levels of three stress factors and norepinephrine.Results:After treatment,the ET-1 level was lower in the observation group than in the control group(P<0.05),and the NO level was higher than in the control group(P<0.05).The inflammatory related factors in the observation group were:IL-6,TNF-α,hs-CRP The level of and was significantly lower than that of the control group(P<0.05).The levels of SOD and GSH-px in the observation group were higher than those in the control group(P<0.05),and the levels of MDA were lower in the observation group than in the control group(P<0.05).Alcohol,epinephrine,and norepinephrine were significantly lower than the control group(P<0.05).Conclusion:Erlotinib treatment of EGFR-sensitive mutant lung adenocarcinoma can significantly improve the vascular endothelial function,reduce the body's inflammatory response and stress response,improve the body's antioxidant capacity,and thus improve the prognosis of patients.
作者
刘丽
杨洋
张万里
杨建英
Liu Li;Yang Yang;Zhang Wanli(Department of Oncology, Meishan Hospital of Traditional Chinese Medicine in Sichuan Province(Meishan 620010))
出处
《陕西医学杂志》
CAS
2018年第10期1275-1277,共3页
Shaanxi Medical Journal
关键词
肺肿瘤/治疗
@表皮生长因子受体
盐酸厄洛替尼
炎症反应
Lung neoplasms/therapy
@Epidermal growth factor receptor
Erlotinib hydrochloride
@Inflammation
